Showing 2,321 - 2,337 results of 2,337 for search '"Xinhua"', query time: 0.10s Refine Results
  1. 2321
  2. 2322
  3. 2323
  4. 2324
  5. 2325
  6. 2326
  7. 2327
  8. 2328
  9. 2329
  10. 2330
  11. 2331
  12. 2332
  13. 2333
  14. 2334
  15. 2335

    The role of propranolol as a radiosensitizer in gastric cancer treatment by Liao XH, Chaudhary P, Qiu G, Che XM, Fan L

    Published 2018-03-01
    “…Xinhua Liao, Prakash Chaudhary, Guanglin Qiu, Xiangming Che, Lin Fan General Surgery Department, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China Purpose: The National Comprehensive Cancer Network guidelines indicate that radiotherapy in gastric cancer shows limited effectiveness at reducing the growth of gastric cancer. …”
    Get full text
    Article
  16. 2336

    The mRNA Expression Profile of Psoriatic Lesion Distinct from Non-Lesion by Li X, Xing J, Wang F, Li J, Li J, Hou R, Zhang K

    Published 2022-09-01
    “…Xinhua Li,1 Jianxiao Xing,1 Fangdi Wang,1 Juan Li,1 Junqin Li,1 Ruixia Hou,1 Kaiming Zhang2 1Shanxi Key Laboratory of Stem Cell for Immunological Dermatosis, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, 030009, People’s Republic of China; 2Shanxi Key Laboratory of Stem Cell for Immunological Dermatosis, Taiyuan Central Hospital, Taiyuan, Shanxi Province, 030009, People’s Republic of ChinaCorrespondence: Kaiming Zhang, Taiyuan Central Hospital, No, 5 Dong San Dao Xiang, Jiefang Road, Taiyuan, Shanxi Province, People’s Republic of China, Tel +86-351-5656080, Email zhangkaiming@sina.comPurpose: Psoriasis is a chronic recurring autoimmune skin disease with a complex etiology and chronic progression; however, its molecular mechanisms remain unclear.Patients and Methods: We performed transcriptomic analysis to profile the mRNA expression of psoriatic lesions (PL) and non-lesion (NL) tissues from psoriasis patients along with normal skin from healthy donors. …”
    Get full text
    Article
  17. 2337

    Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance by Zou X, Xu Q, You R, Yin G

    Published 2023-02-01
    “…Xinhua Zou, Qingyu Xu, Ran You, Guowen Yin Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, People’s Republic of ChinaCorrespondence: Guowen Yin, Tel +86-19868589105, Email jsnjgwy@163.comPurpose: To evaluate the efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor as a second-line therapy for hepatocellular carcinoma after sorafenib resistance.Materials and Methods: The clinical data of 76 patients with hepatocellular carcinoma who were drug-resistant to sorafenib from September 2018 to May 2022 in the tumor intervention department were collected. …”
    Get full text
    Article